← News
Stocks· May 07, 2026 at 06:14 AM
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Authored by·Editorially reviewed
Onur Erkan YıldızFounder, Financial Engineer · CMB-licensed
Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
NeutralMedium impact
AI summary
Angelini Pharma has entered into a definitive agreement to acquire Catalyst Pharmaceuticals.
AI commentary is generated from public news feeds and is not investment advice.
Related coverage
StocksMedium impactNeutral1h
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B
via SeekingAlpha
StocksMedium impactNeutral2h
Should You Invest in This Artificial Intelligence (AI) IPO Stock That Has a Partnership with Amazon?
via Yahoo Finance
NVDA
StocksMedium impactNeutral2h
Does AEO’s Pivot To Amazon And Buybacks Reshape The Margin-Improvement Bull Case For American Eagle?
via Yahoo Finance
AMZN